HTTR 2024 Highlights-2024 HTTR Highlights

Video Transcription

Video Summary

In the ILSLC webinar focused on intolerance and resistance to targeted therapy in non-small cell lung cancer, experts, including Dr. Christian Rolfo, Dr. Kenichi Suda, and several distinguished speakers, discussed the challenges and advancements in targeted cancer therapies. Dr. Passiani highlighted strategies to tackle resistance in oncogenic alterations in cancer, emphasizing the use of combination therapies to improve outcomes. He noted that targeted therapies, although beneficial, often do not completely eliminate cancer due to acquired resistance. Dr. Passiani also discussed the potential of BCLXL inhibitors in overcoming this resistance.<br /><br />Dr. Triparna Sen addressed the transformation of EGFR mutant lung adenocarcinomas to resistant forms, such as small cell lung cancer, emphasizing the significance of P53 loss and MYC overexpression in this transformation. Research into epigenetic factors was also highlighted as crucial for understanding and potentially reversing this resistance.<br /><br />Lastly, Dr. Lisa Hendricks explored antibody-drug conjugates (ADCs) as tools for overcoming TKI resistance, focusing on their promise in treating genes like TROP2 and MET. Challenges remain, such as achieving effective CNS activity and identifying biomarkers to tailor ADC therapy to specific patient needs.<br /><br />Overall, the webinar showcased the complexity of resistance mechanisms and emphasized the need for continued research and multi-faceted treatment approaches in lung cancer therapy.

Keywords

non-small cell lung cancer

targeted therapy

cancer resistance

combination therapies

BCLXL inhibitors

EGFR mutant lung adenocarcinomas

antibody-drug conjugates

TKI resistance

biomarkers